Ameliorating effect of erythropoietin in a severe case of COVID-19: case report

The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Maufak, Mais Mamoon, Khan, Gulfaraz, Purushothaman, Ani, Ahamed, Fiaz, Jallo, Mahir Khalil, Rizwan, Muhammad, Kumar, Sangeeth, Almansouri, Ahmed, Almansoori, Taleb Mohamed, Ouseppachen, Megha Thottappillil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883794/
https://www.ncbi.nlm.nih.gov/pubmed/36762166
http://dx.doi.org/10.11604/pamj.2022.43.129.35014
Descripción
Sumario:The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the standard interventions and continued to deteriorate. On day 22 of his illness, after informed consent, the patient was administered 4000IU of erythropoietin (EPO) subcutaneously, in the hope of improving his O(2) saturation. Positive response was observed in the patient within 24 hours. This prompted us to continued EPO treatment for a total of 42 days until full recovery and discharge. Our findings warrant further studies to ascertain the use of EPO in severe cases COVID-19.

Ejemplares similares